Scientific exchange · Dr. Chloé Dubois

15 Feb 2026 · Phone · Dr. Chloé Dubois, Osaka University Hospital · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0061—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response
Elderly / ECOG 2 patients
Infusion-reaction management

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?
How should grade 2 infusion reactions be managed without steroids?

Notes

Scientific exchange with pathologist at Osaka University Hospital. Discussed duration of response, elderly / ecog 2 patients, infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 2
Depth of exchange: 2
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0061

Audit history (0)

All create, update and approval events for this record

No audit events in sample data